Quadrant Capital Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-139
| Closed | -$18.3K | – | 2741 |
|
|
2025
Q1 | $18.3K | Buy |
139
+90
| +184% | +$11.2K | ﹤0.01% | 2061 |
|
|
2024
Q4 | $4.09K | Hold |
49
| – | – | ﹤0.01% | 2351 |
|
|
2024
Q3 | $3.59K | Hold |
49
| – | – | ﹤0.01% | 2387 |
|
|
2024
Q2 | $3.36K | Buy |
49
+4
| +9% | +$277 | ﹤0.01% | 2383 |
|
|
2024
Q1 | $3.11K | Hold |
45
| – | – | ﹤0.01% | 2416 |
|
|
2023
Q4 | $3.22K | Buy |
45
+33
| +275% | +$1.9K | ﹤0.01% | 2375 |
|
|
2023
Q3 | $626 | Sell |
12
-4
| -25% | -$233 | ﹤0.01% | 2539 |
|
|
2023
Q2 | $1.01K | Hold |
16
| – | – | ﹤0.01% | 2497 |
|
|
2023
Q1 | $867 | Buy |
16
+7
| +78% | +$338 | ﹤0.01% | 2554 |
|
|
2022
Q4 | $476 | Sell |
9
-73
| -89% | -$3.66K | ﹤0.01% | 2628 |
|
|
2022
Q3 | $4K | Sell |
82
-30
| -27% | -$1.57K | ﹤0.01% | 2244 |
|
|
2022
Q2 | $6K | Buy |
112
+103
| +1,144% | +$5.84K | ﹤0.01% | 1924 |
|
|
2022
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 2428 |
|
|
2021
Q4 | $0 | Buy |
9
+5
| +125% | +$210 | ﹤0.01% | 2729 |
|
|
2021
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 2688 |
|
|
2021
Q2 | $0 | Sell |
4
-15
| -79% | -$554 | ﹤0.01% | 2604 |
|
|
2021
Q1 | $1K | Buy |
+19
| New | +$659 | ﹤0.01% | 2325 |
|
|
2020
Q4 | – | Sell |
-8
| Closed | – | – | 2393 |
|
|
2020
Q3 | $0 | Sell |
8
-13
| -62% | -$297 | ﹤0.01% | 2339 |
|
|
2020
Q2 | $1K | Buy |
+21
| New | +$425 | ﹤0.01% | 2167 |
|
Other funds holding ITCI
Quadrant Capital Group's ITCI Position: Q2 2025 in Review
Quadrant Capital Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 139 shares — an estimated $18.3K sold.
Quadrant Capital Group first reported a position in ITCI in Q2 2020 and held it in 19 quarters. The position peaked at $18.3K in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Quadrant Capital Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Quadrant Capital Group sold 139 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $18.3K.
- Quadrant Capital Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 19 quarters.
- Quadrant Capital Group's Intra-Cellular Therapies Inc. position peaked at $18.3K in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.